The University of Kentucky Markey Cancer Center recently launched its own Molecular Tumor Board, an approach to cancer care that uses genetic analysis to help oncologists choose cancer therapies tailored to each patient’s individual needs. The Molecular Tumor Board is the latest precision medicine initiative to come online at Markey.
“Oncology is now more genetic-based, whereas before it was based upon tumor types,” said Dr. Mark Evers, director of the UK Markey Cancer Center. “Through understanding the genetic makeup of our patients and their tumors, we can then help to direct their therapy.”
The Molecular Tumor Board is co-directed by clinical pharmacologist Jill Kolesar, Pharm.D., who recently joined Markey and the UK College of Pharmacy after starting a similar initiative at the University of Wisconsin-Madison, and Markey gynecologic oncologist Dr. Rachel Miller.
Read more at UK Now.